Corbion
Market Cap
€2.7b
Last Updated
2021/06/14 23:49 UTC
Data Sources
Company Financials +
Executive Summary
Corbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet with proven track record.
Similar Companies
Share Price & News
How has Corbion's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRBN is not significantly more volatile than the rest of Dutch stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: CRBN's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-1.4%
CRBN
0.3%
NL Chemicals
1.3%
NL Market
1 Year Return
40.4%
CRBN
35.9%
NL Chemicals
35.5%
NL Market
Return vs Industry: CRBN exceeded the Dutch Chemicals industry which returned 35.9% over the past year.
Return vs Market: CRBN exceeded the Dutch Market which returned 35.5% over the past year.
Shareholder returns
| CRBN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.4% | 0.3% | 1.3% |
| 30 Day | -3.3% | 2.9% | 3.9% |
| 90 Day | 4.9% | 11.7% | 5.4% |
| 1 Year | 44.5%40.4% | 38.3%35.9% | 37.8%35.5% |
| 3 Year | 79.0%70.4% | 60.0%41.6% | 32.9%20.5% |
| 5 Year | 138.9%114.6% | 154.0%106.9% | 80.4%50.0% |
Long-Term Price Volatility Vs. Market
How volatile is Corbion's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Type Of Shareholders Own The Most Number of Corbion N.V. (AMS:CRBN) Shares?4 weeks ago | Simply Wall St
Don't Race Out To Buy Corbion N.V. (AMS:CRBN) Just Because It's Going Ex-Dividend1 month ago | Simply Wall St
Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The BusinessValuation
Is Corbion undervalued compared to its fair value and its price relative to the market?
37.29x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CRBN (€46.32) is trading above our estimate of fair value (€27.55)
Significantly Below Fair Value: CRBN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRBN is poor value based on its PE Ratio (37.3x) compared to the Dutch Chemicals industry average (32.3x).
PE vs Market: CRBN is poor value based on its PE Ratio (37.3x) compared to the Dutch market (29.4x).
Price to Earnings Growth Ratio
PEG Ratio: CRBN is poor value based on its PEG Ratio (3.6x)
Price to Book Ratio
PB vs Industry: CRBN is overvalued based on its PB Ratio (5.3x) compared to the NL Chemicals industry average (3.5x).
Future Growth
How is Corbion forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
10.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRBN's forecast earnings growth (10.2% per year) is above the savings rate (0.1%).
Earnings vs Market: CRBN's earnings (10.2% per year) are forecast to grow slower than the Dutch market (17.2% per year).
High Growth Earnings: CRBN's earnings are forecast to grow, but not significantly.
Revenue vs Market: CRBN's revenue (3.9% per year) is forecast to grow slower than the Dutch market (6.5% per year).
High Growth Revenue: CRBN's revenue (3.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRBN's Return on Equity is forecast to be low in 3 years time (13.5%).
Past Performance
How has Corbion performed over the past 5 years?
-20.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRBN has high quality earnings.
Growing Profit Margin: CRBN's current net profit margins (7.4%) are higher than last year (2.6%).
Past Earnings Growth Analysis
Earnings Trend: CRBN's earnings have declined by 20.6% per year over the past 5 years.
Accelerating Growth: CRBN's earnings growth over the past year (183.4%) exceeds its 5-year average (-20.6% per year).
Earnings vs Industry: CRBN earnings growth over the past year (183.4%) exceeded the Chemicals industry 20.7%.
Return on Equity
High ROE: CRBN's Return on Equity (14.2%) is considered low.
Financial Health
How is Corbion's financial position?
Financial Position Analysis
Short Term Liabilities: CRBN's short term assets (€385.1M) exceed its short term liabilities (€233.9M).
Long Term Liabilities: CRBN's short term assets (€385.1M) exceed its long term liabilities (€324.6M).
Debt to Equity History and Analysis
Debt Level: CRBN's debt to equity ratio (54.6%) is considered high.
Reducing Debt: CRBN's debt to equity ratio has increased from 31.6% to 54.6% over the past 5 years.
Debt Coverage: CRBN's debt is well covered by operating cash flow (38.7%).
Interest Coverage: CRBN's interest payments on its debt are well covered by EBIT (10x coverage).
Balance Sheet
Dividend
What is Corbion current dividend yield, its reliability and sustainability?
1.21%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CRBN's dividend (1.21%) isn’t notable compared to the bottom 25% of dividend payers in the Dutch market (1.57%).
High Dividend: CRBN's dividend (1.21%) is low compared to the top 25% of dividend payers in the Dutch market (4.46%).
Stability and Growth of Payments
Stable Dividend: CRBN's dividend payments have been volatile in the past 10 years.
Growing Dividend: CRBN's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (45.1%), CRBN's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CRBN's dividends in 3 years are forecast to be well covered by earnings (37.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.8yrs
Average management tenure
CEO
Olivier Rigaud (57 yo)
1.83yrs
Tenure
€1,251,000
Compensation
Mr. Olivier Rigaud serves as Chief Executive Officer and Chairman of the Management Board at Corbion N.V. since August 8, 2019. Mr. Rigaud served as Chief Executive Officer of Naturex S.A. since October 1,...
CEO Compensation Analysis
Compensation vs Market: Olivier's total compensation ($USD1.52M) is about average for companies of similar size in the Dutch market ($USD2.15M).
Compensation vs Earnings: Olivier's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: CRBN's management team is seasoned and experienced (6.8 years average tenure).
Board Members
Experienced Board: CRBN's board of directors are considered experienced (6.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Corbion N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Corbion N.V.
- Ticker: CRBN
- Exchange: ENXTAM
- Founded: 1919
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: €2.727b
- Shares outstanding: 58.87m
- Website: https://www.corbion.com
Number of Employees
Location
- Corbion N.V.
- Piet Heinkade 127
- Amsterdam
- Noord-Holland
- 1019 GM
- Netherlands
Listings
Biography
Corbion N.V. provides lactic acid and lactic acid derivatives, emulsifiers, functional enzyme blends, minerals, vitamins, and algae ingredients worldwide. The company offers ingredient solutions made from ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/14 23:49 |
| End of Day Share Price | 2021/06/14 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.